These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32106752)

  • 1. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties.
    Zhang J; Huang Y; Xi G; Zhang F
    MAbs; 2020; 12(1):1724751. PubMed ID: 32106752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human
    Burova E; Hermann A; Waite J; Potocky T; Lai V; Hong S; Liu M; Allbritton O; Woodruff A; Wu Q; D'Orvilliers A; Garnova E; Rafique A; Poueymirou W; Martin J; Huang T; Skokos D; Kantrowitz J; Popke J; Mohrs M; MacDonald D; Ioffe E; Olson W; Lowy I; Murphy A; Thurston G
    Mol Cancer Ther; 2017 May; 16(5):861-870. PubMed ID: 28265006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
    DeAngelis N; Ferrante C; Powers G; Sendecki J; Mattson B; Pizutti D; Packman K; Wang W; Trouba K; Nanjunda R; Wheeler J; Brittingham R; Wu SJ; Luo J; Lorenzi MV; Verona RI
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):515-527. PubMed ID: 35298699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
    Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
    MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical and Immunological Characterization and
    Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
    Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
    Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
    Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
    Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy.
    Chen YL; Cui Y; Liu X; Liu G; Dong X; Tang L; Hung Y; Wang C; Feng MQ
    J Biol Chem; 2021 Dec; 297(6):101420. PubMed ID: 34798072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
    Zhang T; Song X; Xu L; Ma J; Zhang Y; Gong W; Zhang Y; Zhou X; Wang Z; Wang Y; Shi Y; Bai H; Liu N; Yang X; Cui X; Cao Y; Liu Q; Song J; Li Y; Tang Z; Guo M; Wang L; Li K
    Cancer Immunol Immunother; 2018 Jul; 67(7):1079-1090. PubMed ID: 29687231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
    Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
    PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
    Li F; Li J; Yin K; Zhang J; Li ZH; Lu L; Bao YW; Qin Z; Zheng Y; Yang BT; Li J; Wang X
    Acta Pharmacol Sin; 2021 Jan; 42(1):142-148. PubMed ID: 32467569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.